EuroSciCon hosted the “Biomaterial 2020”, during January 4-5, 2020, which was a great success. Eminent keynote speakers from various reputed institutions and organizations addressed the gathering with their resplendent presence.

We extend our grateful thanks to all the momentous speakers, conference attendees who contributed towards the successful run of the conference.

Biomaterial 2020 witnessed an amalgamation of peerless speakers who enlightened the crowd with their knowledge and confabulated on various latest and exciting innovations in all areas of Biomaterial Engineering.

Biomaterial 2020 Organizing Committee extends its gratitude and congratulates the Honorable Moderators of the conference.

EuroSciCon extends its warm gratitude to all the Honorable Guests and Keynote Speakers of “Biomaterial 2020 Conference”.

• Jean marie dubois, University of Lorraine, France
• Thomas J Webster, Northeastern University, USA

EuroSciCon Ltd is privileged to felicitate Biomaterial 2020 Organizing Committee, Keynote Speakers, Chairs and also the Moderators of the conference whose support and efforts made the conference to move on the path of success. EuroSciCon LTD thanks every individual participant for the enormous exquisite response. This inspires us to continue organizing events and conferences for further research in the field of Biomaterial.

EuroSciCon is glad to announce its “International Online Conference on Biomaterials and Biomedical Engineering” which will be held during October 05-06, 2020. We cordially welcome all the eminent researchers, Presidents, CEO’s, researchers, industrialists, young scientists, Training Institutes, Young researchers, Data Management Companies, Manufacturing Devices Companies, students and delegates to take part in this upcoming conference to witness invaluable scientific discussions and contribute to the future innovations in the field of Biomaterial with 20% abatement on the Early Bird Prices.

Bookmark your dates for “Biomaterial Webinar 2020” as the Nominations for Best Poster Awards and Young Researcher Awards are open across the world.

The new medical technologies are transforming the delivery and management of health care.  The investment and interest in research, design and development of new medical technologies are growing and making their way into the healthcare systems at a faster rate than ever. Whilst the scientists, engineers and clinicians collaborate in the bringing of new medical technologies to the commercial stage, there are three main factors to ensure their approval, namely quality, efficacy (performance) and safety.  These aspects of the technology are subjected to regulatory scrutiny and approval process by Regulatory Agencies or Authorities. 

Typical responsibilities of a Regulatory Agency or Authority (e.g. US FDA, UK MHRA, Germany ZLG, Netherlands IGZ, and Ireland HPRA) are protecting the public health by ensuring the quality, safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices; and the scope may be extended to cover ensuring the safety of food supply, cosmetics, and products. Some agencies are responsible for advancing the public health by helping to speed innovations that make medical products more effective, safer, and more affordable and by helping the public get the accurate, science-based information they need to use medical products and foods to maintain and improve their health.

The regulatory approval processes are based on scientific, technical and clinical evidence that the appropriate tests, verifications and validations have been conducted to support the clinical claims as per the approved indication(s) for use with adequate information to ensure the medical device can be used as intended. No biomaterial progresses to be considered as medical device for use without being subjected to some regulatory scrutiny.IMDRF has been working on the harmonisation of regulations at the global level to help facilitate the process of meeting the regulatory requirements and bringing new technologies to the end-users. This promotes Mutual Recognition Agreement (MRA) to allow inspectors to rely upon information from inspections conducted within each other’s borders.

As in the case of COVID-19, patients develop respiratory failure thus requiring assistance in the form of endotracheal intubation. Given the nature of this process, healthcare providers are at risk of contracting the virus via droplets either exhaled or coughed out by the patient. The intubation box allows having this protection in place by limiting the infection within the box's volume around the patient.

Conclusion & Significance: The device functions as an aerosol obstruction box which is placed atop the patient bed on the head-side, limiting the flow of virus-laden droplets from the patient to the doctor, especially during the process of intubation.

Raman spectroscopy is a non-invasive and label-free technology. Cells, the fundamental units of life, are the basis for understanding the processes of life, as well as the mechanism of diseases. Single cell research is an emerging field of biology which promises new insight into phenotypic heterogeneity in isogenic cell population. However, there are a great many of challenges, such as non-invasive cell analysis and in situ single cell sorting from complex samples, in front of single cell biotechnology. Single cell Raman spectroscopy (SCRS) is a non-invasive and label-free vibrational spectroscopy technique, which can provide intrinsic chemical fingerprint of an individual cell, possesses tremendous potential applications in every fields of life sciences.

Recently we developed a new type of single cell sorting system which combines Raman spectroscopy and cell separation based on laser-matter interaction which has advantages of visualization, pinpoint accuracy and label-free. We had successfully recognized and isolated various kinds of cells from a series of complex biological samples, such as seawater, soil and gut microbiome. Furthermore, the isolated cells can be used for sequencing, culture and other follow up studies. To combine single cell sorting with single cell sequencing technology could build the relationship between cell phenotypes and genotypes, which will help us to uncover fundamental biological mechanisms. We have also successfully achieved single cell culture of isolated cells, which provides an innovative strategy for engineering cell screening and uncultured microorganisms studies. Single cell sorter can also be coupled with mass spectrometry to shorten the detection period of pathogens by skipping culture step which often takes several days. In consideration of the wide applications of single cell Raman and sorting technique, it will surely bring significant breakthroughs in all branches of life sciences and biomedicine.

statement of the Problem: Alzheimer’s disease (AD) is incurable and presently 47 million of people worldwide suffer from it. Early intervention, particularly prior to the onset of any disease symptoms, may offer an opportunity to stop or delay the disease progression. Amyloid-β (Aβ) peptides/species are one of the highly important biomarkers and drug target for AD. Thus, development of sensitive probes to detect the presence and monitor the progression of these Aβ deposits is of paramount importance for early diagnosis from which early intervention and delaying measures can be performed. Practice: we have designed, synthesized and spectroscopically characterized a novel series of donor-acceptor type cyanine fluorophores for its potential as a NIR fluorescence probe for in vivo imaging of Aβ in AD mouse model. Among them, DBAN was found to exhibit excellent functional properties for Aβ imaging including strong NIR fluorescence enhancement upon binding with Aβ species, high selectivity toward Aβ species, good biocompatibility and stability, and excellent blood-brain barrier (BBB) permeability. Importantly, DBAN was successfully applied for in vivo and ex vivo imaging of Aβ in AD mouse model. In addition, DBAN showed effective inhibitory effect on Aβ aggregation, significant neuroprotection effect against the Aβ-induced toxicities, and suppression on Aβ-induced ROS generation signifying its great promise as a theranostic agent for the early diagnosis and therapy of AD.

Conclusion & Significance: A novel NIR fluorescence turn-on probe for real-time imaging of Aβ in AD mouse model and simultaneously, protecting against the Aβ-induced toxicity was designed, developed and experimentally demonstrated. Our design strategy provides insights into the design and development of an effective theranostic NIR imaging probe to target Aβ species for the early diagnose and treatment of AD.

Statement of the Problem: CD9 is a protein that drives growth of stem cells, and which could be a target for new treatments, has been identified by researchers at the Stanford University. The researchers altered the amount of CD9 in stem cells and their-derived exosomes in mice and found that increasing levels of CD9 made stem cells more proliferative and enhanced the therapeutic index of exosomes drug delivery .Exosomes are extracellular vesicles that carry a cargo of therapeutic proteins, which have shown promising potential in regenerative medicine applications. It has previously been demonstrated that CD9 can enhance the therapeutic effect of stem cell therapies. However, the effect of CD9 on exosome therapy remains largely unexplored. In the present study, we analyzed the effect of exosome therapy, combined with CD9 expression. CD9 overexpressed exosomes significantly improved the repair process of damages tissues. This protective effect was mediated by a reduction in inflammation, increased cell proliferation, and decreased apoptosis. We identified several pathways through which exosomes and CD9 synergistically exert their therapeutic effect, including upregulation of FoxO signaling. Thus, CD9 may be a promising strategy for enhancing the therapeutic efficacy of exosome treatment.

Conclusion & Significance: CD9 protein is both linked to stem cells proliferation and growth, this could guide the development of new treatments that are targeted at the protein. CD9 protein could therefore be used as a marker to identify stem cells proliferation rate.